In addition, the drug JQ1 also restores the cellular function of neurons in human models of the disease. Rett Syndrome causes severe deficits in language, learning and other brain functions and eventually leads to death, often during teenage years.

The Yale team -- led by senior author In-Hyun Park, associate professor of genetics, and a researcher at Yale's Child Study Center and Stem Cell Center -- wanted to know how a mutation in gene MECP-2 causes the severe disruption to neuronal functions in the cortex of Rett Syndrome patients.

They created a human brain organoid containing this mutation from embryonic stem cells and found severe abnormalities in multiple brain cells. A type of brain cell called interneurons, which regulate the brain's excitatory neurons, was particularly impacted by the mutation.

The lab then screened a variety of compounds and found that one drug, JQ1, corrected abnormalities found in interneurons of the Rett Syndrome model. The drug has been investigated in several experimental trials as a potential cancer treatment. They then tested the drug in mice models of Rett Syndrome and found that the treated mice lived about twice as long as those not receiving the drug.

Park said the research paves the way for additional research on potential new therapies for Rett Syndrome, for which there are currently no effective treatments.

Story Source:

Materials provided by Yale University. Original written by Bill Hathaway. Note: Content may be edited for style and length.

Journal Reference:

1. Yangfei Xiang, Yoshiaki Tanaka, Benjamin Patterson, Sung-Min Hwang, Eriona Hysolli, Bilal Cakir, Kun-Yong Kim, Wanshan Wang, Young-Jin Kang, Ethan M. Clement, Mei Zhong, Sang-Hun Lee, Yee Sook Cho, Prabir Patra, Gareth J. Sullivan, Sherman M. Weissman, In-Hyun Park. Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons. Molecular Cell, 2020; DOI: 10.1016/j.molcel.2020.05.016